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Abstract
Background: Altered gene expression is an important feature of ischemic cerebral injury and
affects proteins of many functional classes. We have used microarrays to investigate the changes in
gene expression at various times after middle cerebral artery occlusion in human and rat brain.
Results: Our results demonstrated a significant difference in the number of genes affected and the
time-course of expression between the two cases. The total number of deregulated genes in the
rat was 335 versus 126 in the human, while, of 393 overlapping genes between the two array sets,
184 were changed only in the rat and 36 in the human with a total of 41 genes deregulated in both
cases. Interestingly, the mean fold changes were much higher in the human. The expression of novel
genes, including p21-activated kinase 1 (PAK1), matrix metalloproteinase 11 (MMP11) and
integrase interactor 1, was further analyzed by RT-PCR, Western blotting and
immunohistochemistry. Strong neuronal staining was seen for PAK1 and MMP11.
Conclusion: Our findings confirmed previous studies reporting that gene expression screening
can detect known and unknown transcriptional features of stroke and highlight the importance of
research using human brain tissue in the search for novel therapeutic agents.
Background
Ischaemic stroke results from obstruction of blood flow in
a major cerebral vessel and leads to deregulation of genes
whose expression promotes ischemic neuronal death and
subsequent neurological dysfunction [1,2]. Under
ischemic conditions, energy metabolism fails, and severe
reduction in mRNA and protein synthesis occurs in the
ischemic core region. The tissue surrounding this area
(peri-infarcted region) is able to maintain some functions,
such as ionic homeostasis and can be partially salvaged by
blood recirculation [3,4].
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The precise molecular mechanisms involved in ischemia-
induced brain injury remain poorly understood. Limited
knowledge of the molecular mechanisms involved in tis-
sue regeneration has been gained from animal experi-
ments using the middle cerebral artery occlusion (MCAO)
model which replicates, in many aspects, the neuropatho-
logical changes following stroke in humans [5]. Although
the contralateral side of the brain is not totally unaffected
by ischemic damage, the collection of experimental and
reference control tissue from the same animal is a better
comparison than using sham-operated control in rats,
while in human samples the only control tissue available
is contralateral hemisphere. In addition, using contralat-
eral tissue as a control and the direct comparison with
stroke hemisphere provides the best model for validation
as it removes inter-patient genetic variation and also min-
imises the differences in potential degradation between
the target and reference mRNAs. This has been applied
previously in both human [6,7] and animal [8-10] stud-
ies. Rao et al. in particular observed very few differences in
gene expression between sham and contralateral cortex at
24 h of reperfusion following MCAO in the rat [9].
Analysis of ischemic brain tissue with techniques capable
of studying multiple transcripts simultaneously can iden-
tify gene expression changes previously not known to be
implicated in ischemic pathophysiology and may lead to
development of new targets for stroke therapy [11]. DNA
microarray technology has been used to investigate the
expression of thousands of genes in a single hybridization
experiment. Several experimental studies have examined
alteration of gene expression in the postischemic rat brain
using microarray technology [8-10,12-18], while blood
genomic profiling in human stroke have been investigated
in recent pilot studies [19,20] (Table 1). Critical compari-
son of gene expression profiles after stroke in humans
with those in animal models may lead to a better under-
standing of the pathophysiology of brain ischaemia and
allow an evaluation of the usefulness of animal models in
stroke research.
Until recently, gene expression profiling had not been
applied to patients dying of ischemic stroke, in part
because human brain autopsies are not regularly
obtained. Although tissue obtained from brain autopsies
is generally of lower quality than that of brain biopsies
obtained from living patients, the majority of RNA tran-
scripts and proteins in the human brain are reasonably
stable (compared to other tissues such as blood and kid-
ney) and degrade to only a minor degree following death,
thus making autopsy tissue a useful source for the isola-
tion of nucleic acids and proteins [21]. Previous studies
evaluating the mRNA quality in human post-mortem
brain tissue have demonstrated a minimal effect upon
their overall relative stability and indicated that frozen
brains up to 72 hours post-mortem can be efficiently ana-
lyzed [22]. In line with that, in previous human brain
studies, tissue was obtained up to a maximum of 6 hours
[7], 40 hours [23], 45 hours [24] and 69 [6] hours follow-
ing death. Moreover, after comparing mRNA levels in
autopsies and biopsies, Castensson et al. [25] found a gen-
eral similarity in the levels between the two groups, and
suggested that mRNA levels in brain autopsy samples can
provide clues about the brain in vivo. Interestingly, Alme-
ida et al. [26] found that, even if performed on degraded
RNA, RT-PCR can be used to provide a reliable estimate of
in vivo mRNA levels, maybe due to the similarities in the
rates of degradation between the target and reference
mRNAs. Recently, Vikman and Edvinsson [27] investi-
gated the gene expression in human brain after ischaemia
using samples 7–10 days post-stroke; however, they
obtained their samples after a considerable delay of 2–3
days post-mortem and they focused mainly on mRNA
expression of receptors.
To identify the genes whose expression was changed in
the human brain following ischaemia, we investigated the
dynamic changes in gene expression in brain samples
(collected within 6 h of death) from patients with various
times of survival (2–37 days; Table 2) following stroke
and compared them with those at various time-points (1
hour – 21 days) following middle cerebral artery occlu-
sion (MCAO) in rats. The Atlas 1.2 cDNA microarray was
used to screen for differential expression of 1176 genes
and significantly de-regulated genes were selected through
image analysis. We further investigated whether the
altered mRNA and protein levels of a subset of deregu-
lated molecules in the postischemic brain could be repro-
duced in an in vitro model of neuronal and endothelial
cell culture under conditions of oxygen-glucose depriva-
tion (OGD). The findings confirmed previous studies
reporting that parallel screening of gene expression can
detect both previously documented and novel transcrip-
tional features of the cerebral response to ischemia, and
demonstrated significant differences in gene expression
between human stroke and the animal model.
Results
cDNA microarray analysis
The expression of ischemia-related genes was determined
by comparing the infarct-induced expression (combined
samples from infarcted and peri-infarcted areas) to that in
the contralateral hemisphere: 77, 92 and 15 genes were
de-regulated in stroke-affected regions in the 3 patient sur-
vival groups respectively, while 9, 51, 48, 166, 253, 117
and 261 genes were altered at the 7 different time-points
in the animal model compared to the controls (Figure 1).
The combined number of differentially expressed tran-
scripts in stroke patients represented 6.5%, 7.8% and
1.3% respectively in each survival group of the totalB
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) Table 1: Previous studies employing microarray approaches to study stroke
Soriano et al. 
2000
Jin et al. 2001 Kim et al. 
2002
Rao et al. 2002 Schmidt-
Kastner et 
al. 2002
Tang et al. 
2002
Roth et al. 
2003
Kim et al. 2004 Lu et al. 
2004
Moore et al. 2005 Ford et al. 
2006
Tang et al. 
2006
Vikman and 
Edvinsson 2006
Our data
Material 
used
Rat brain 
tissue
Rat brain tissue Rat brain 
tissue
Rat brain tissue Rat brain 
tissue
Rat brain 
tissue
Rat brain 
tissue
Rat brain tissue Rat brain 
tissue
Rat brain 
tissue
Model of 
ischemia
Permanent 
focal MCAO
Transient 
global MCAO
Permanent 
focal 
MCAO
Transient focal 
MCAO
Transient 
focal 
MCAO
Permanent 
focal 
MCAO
Permanent 
focal MCAO
Transient focal 
MCAO
Transient 
focal 
MCAO
Blood from 
ischemic stroke 
patients
Permanent 
and 
transient 
focal 
MCAO
Blood from 
ischemic 
stroke 
patients
Post-mortem 
brain tissue 
from 11 stroke 
patients
Post-mortem 
brain tissue 
from 12 
stroke 
patients and 
permanent 
focal rat 
MCAO
No of 
genes
750 374 1176 1263 9044 ~8,000 ~13,000 5,000 1,322 ~19,000 8784 ~39,000 7458 1176
Time after 
ischemia
3 hours 4 hours
24 hours
72 hours
6 hours 6 hours
24 hours
5 hours 24 hours 1 hours
3 hours
6 hours
24 hours
3 hours
6 hours
12 hours
1 days
2 days
4 days
30 min
4 hours
8 hours
24 hours
3 days
7 days
As soon as possible 
after hospitalization
24 hours 3 hours
5 hours
24 hours
7–10 days 
(obtained 2–3 
days post-
mortem)
1 hour-21 
days (rat) and 
2–37 days 
(human, 
obtained by 6 
hours post-
mortem)
Cut-off 
values
2.0-fold 1.7-fold 2.0-fold 2.5-fold 1.7-fold 2.0-fold 3.0-fold 2.0-fold 2.0-fold - 2.0-fold 1.5-fold - 2.0-fold
Confirmat
ion of 
results
In situ 
hybridization, 
western 
blotting
Western 
blotting, 
immuno-
histochemistry
RT-PCR Real-time PCR, 
antisense 
knockdown, 
western 
blotting, 
immuno-
histochemistry
Microarray 
analysis 
only
Real-time 
RT-PCR
Cell culture, 
in situ 
hybridization, 
western 
blotting, 
immuno-
fluorescence
Cell culture, 
northern 
blotting, RT-
PCR, western 
blotting, 
immuno-
histochemistry
Real-time 
RT-PCR
Real-time 
RT-PCR
Microarray 
analysis 
only
Microarray 
analysis 
only
Real-time PCR, 
immuno-
histochemistry
Cell culture, 
RT-PCR, 
western 
blotting, 
immuno-
histochemistr
y, immuno-
fluorescence
Selected 
molecules
NGFI-C
ARC
GRB2
SMN1
IFN-IP
NDGAP-1
NPR
SOCS-3 NARP
SPR
SPIN2C
ARG1
LBP
PC4 FAK Synaptic 
proteins
CD14
CD36
FcGR2A
IFNGR1 caspase-1 
a-catenin
LY64
ELK3
POU3F4
RHOA
PAK1
MMP11
INI1B
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Table 2: Clinical Details of Patients
Patient no. Age/sex Survival 
after 
stroke
NIHSS on 
admission
Hypertensiona Coronary 
artery 
disease
Atrial 
fibrillation
History of 
TIA/
previous 
stroke
Hypercholesterolemiab Smoking Obesityc Cause of death Antiplatelets Statinsd RSA-be
1 63/F 2 days 26 Yes No No No No No No Large ischemic 
stroke
No No Yes
2 84/M 3 days 21 Yes Yes No No No Yes No Malignant stroke No No No
3 68/M 3 days 24 Yes Yes No No Yes No No Brain oedema No No Yes
4 84/M 6 days 22 Yes Yes No No No No No Cardiac failure Yes Yes No
5 51/M 9 days 25 Yes No No Yes No No No Respiratory 
infection
Yes No No
6 74/M 15 days 22 Yes Yes No No No No Yes Heart attack Yes No Yes
7 86/M 15 days 14 Yes Yes No No Yes No No Urinary infection Yes No No
8 58/M 17 days 16 Yes Yes No No Yes Yes No Cardiac infarction Yes No No
9 74/M 20 days 12 Yes Yes No No No No No Bronchial 
aspiration
Yes No No
10 73/M 26 days 14 Yes Yes No No Yes No Yes Respiratory 
infection
Yes No Yes
11 75/M 29 days 20 No Yes Yes No No Yes No Septic shock Yes No Yes
12 60/F 37 days 18 Yes Yes No No Yes Yes No Pulmonary 
embolism
Yes No No
a Blood pressure greater than 135/85 mmHg.
b Serum total cholesterol levels greater than 5.2 mmol.
c Body mass index greater than 30.
d Patients who were on statins before the ischemic stroke.
e Patients taking either angiotensin converting enzyme inhibitors or angiotensin type I receptor antagonists.
M = male; F = female; NIHSS = NIH Stroke Scale; TIA = Transient Ischaemic Attack.BMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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Statistical analysis of microarray data Figure 1
Statistical analysis of microarray data. Total number of genes and number of overlapping genes (between the two array 
sets) deregulated following stroke in human and rat (A). Scatter plots representing the data dispersion over two logarithmic 
scales for all time-points in human (B) and rat (C).BMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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number of the genes on the microarray. These findings
compare with 0.8%, 4.3%, 4%, 14.1%, 21.5%, 10% and
22.2% of genes respectively at each time-point in rats.
In total, 126 genes were deregulated after stroke in
humans and 335 in the rat MCAO model. However, these
data are not directly comparable since many transcripts in
the human array were not present in the rat array and vice
versa. Out of a total of 393 genes present in both arrays,
31, 49 and 5 showed deregulated expression in the 3
patient groups respectively, whilst 7, 27, 26, 62, 107, 34
and 107 genes were deregulated at each of the 7 time-
points respectively following rat MCAO (Table 3, Figure
1). Of the 393 overlapping transcripts, the expression of
36 was changed only in the human study, compared with
184 that were altered only in the animal model, while
only 41 deregulated genes were shared between the two
studies. Interestingly, the mean fold changes in the
human data were much higher than in the rat.
Amongst these genes we examined in more detail a small
subset with no prior report of a role in stroke (PAK1,
MMP11 and INI1). PAK1 was only induced in the human
study although present in both microarray sets, MMP11
was induced in both cases, while INI1 was induced in the
human but was not present in the rat microarray set. To
confirm the microarray data, RT-PCR was carried out on
selected deregulated genes. The temporal expression pat-
terns of these genes following RT-PCR showed good
agreement with the corresponding expression profiles
obtained from the microarray analysis, supporting the
validity of the data obtained from the microarrays. Using
Western blotting and immunohistochemistry, PAK1, INI1
and MMP11 protein expression and localization was
determined in the contralateral and ipsilateral brain areas
of individual stroke patients and rats subjected to MCAO,
and in HBMEC and HFN exposed to OGD and reper-
fusion.
Integrase Interactor 1 (INI1)
In agreement with the microarray data, RT-PCR demon-
strated an increase in ini1 mRNA levels in peri-infarcted
and infarcted areas of patients who survived between 2
and 6 days following stroke (Figure 2A). Analysis of INI1
protein expression in samples from individual stroke
patients showed that protein levels were increased in peri-
infarcted and infarcted regions in 8 of 12 samples (Table
4; Figure 2Bi and 2Bii). Only one patient who survived for
3 days after stroke showed decreased protein expression.
Cells from contralateral white matter were not stained for
INI1 but some weak neuronal cytoplasmic staining was
seen in grey matter (Figure 2Ci). An increase in its expres-
sion was observed in the cytoplasm of cells with the mor-
phological appearance of glia and microvessels from peri-
infarcted and infarcted areas of patients surviving for 3 to
29 days after stroke (Figure 2Cii and 2Ciii). In the rat, RT-
PCR and Western blotting demonstrated no notable
changes in INI1 mRNA and protein expression respec-
tively following MCAO. Weak cytoplasmic staining was
observed in contralateral neurons but no differences in
the level of INI1 neuronal expression occurred following
MCAO (data not included). Finally, HFN and HBMEC
exposed to OGD and/or reperfusion showed no difference
in mRNA and protein levels for INI1 when compared with
untreated cells.
Matrix Metalloproteinase 11 (MMP11)
For MMP11, RT-PCR data agreed with the findings from
the microarray study, showing increased mRNA levels in
infarcted and peri-infarcted tissue from patients surviving
2–20 days following stroke (Figure 3Ai). Western blotting
in individual patient samples demonstrated that 6 of 12
patients had elevated MMP11 protein levels (Table 4; Fig-
ure 3Bi and 3Bii). The majority of cells from contralateral
grey and white matter were not stained for MMP11 (Fig-
ure 3Ci). In patients surviving from 3 days to 4 weeks,
endothelial cells and neurons from both infarcted and
peri-infarcted tissue were stained positive for MMP11
(Figure 3Cii and 3Ciii). In the rat model, RT-PCR con-
firmed the microarray data for some of the time-points,
showing no notable change in mRNA levels at 1 and 12 h
but a prolonged upregulation at 3 days following MCAO
(Figure 3Aii). Protein levels were elevated at 1 h, 24 h and
3 days, after which they returned to control levels. No
staining for MMP11 was seen in contralateral areas (Fig-
ure 3Di), but an increase in its expression occurred in neu-
rons following MCAO, in particular at 12 and 24 h (Figure
3Dii). MMP11 mRNA and protein levels remained
unchanged in HFN and HBMEC exposed to conditions of
oxygen-glucose deprivation.
P21-activated kinase 1 (PAK1)
RT-PCR confirmed the upregulation of pak1 determined
by the microarrays in pooled samples from stroke patients
who survived between 2 and 6 days following stroke (Fig-
ure 4A). Western blotting showed an upregulation in the
protein levels of PAK1 in 6 of 12 patients (Table 4; Figure
4Bi and 4Bii). No staining was seen in contralateral white
matter, while, in grey matter, PAK1 stained weakly the
cytoplasm of some neurons (Figure 4Di). In patients sur-
viving for 3 days to 4 weeks after stroke, increased PAK1
nuclear staining was seen in neurons in both peri-inf-
arcted and infarcted regions (Figure 4Dii). In the rat, RT-
PCR showed no significant changes in the mRNA levels
for pak1 at most of the time-points examined. However,
Western blotting showed an upregulation in protein levels
1, 12 and 24 h after MCAO, returning to control levels at
3 days, and becoming downregulated at 7 days following
MCAO (Figure 4Ci and 4Cii). Weak staining was observed
in neurons from the contralateral hemisphere (FigureBMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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Table 3: Genes deregulated in both human and animal stroke microarrays
Human Rat Human Rat
Gene name GenBank SwissProt GenBank SwissProt Max/min Days Max/min Time
c-jun proto-oncogene J04111 P05412 X17163 P17325 4.4-fold 9 – 20 3.5-fold 1 h – 24 h
Matrix metalloproteinase 11 X57766 P24347 U46034 P97568 3.2-fold 2 – 20 2.6-fold 3 days
Calcium/calmodulin-dependent kinase (CAMK1) L41816 Q14012 L24907 Q63450 17.2-fold 2 – 20 0.05-fold 21 days
L26288 Q63084
LIM domain kinase 1 D26309 P53667 D31873 P53669 3.6-fold 2 – 20 2.4-fold 3 days
0.4-fold 21 days
T-Lymphocyte maturation-associated protein M15800 P21145 U31367 Q64349 1.7-fold 2 – 6 0.2-fold 21 days
Retinoic Acid Receptor beta M84820 P28702 M81766 P49743 2.0-fold 2 – 6 0.1-fold 21 days
S54072 P28703
Tyrosine Phosphatase 1B M31724 P18031 M33962 P20417 3.4-fold 2 – 6 0.2-fold 21 days
Adenosine A1 Receptor S56143 P30542 M64299 P25099 2.6-fold 2 – 6 5.2-fold 4 hrs
Growth arrest & DNA damage-inducible 153 S40706 P35638 U30186 Q62804 2.4-fold 2 – 6 2.1-fold 3 days
S62138
Glutamate Decarboxylase 67 M81883 Q99259 M34445 P18088 5.6-fold 2 – 6 2.5-fold 21 days
Glutamate Decarboxylase 65 M81882 Q99259 M72422 Q05683 22.7-fold 2 – 20 2.2-fold 3 days
Neurotrophin 3 M37763 P20783 M34643 P18280 5.1-fold 2 – 37 2.2-fold 12 hrs
Inhibitor of DNA binding 2 M97796 Q02363 D10863 P41137 5.6-fold 2 – 20 0.4-fold 21 days
Neuropeptide Y K01911 P01303 M20373 P07808 8.8-fold 2 – 20 0.04-fold 21 days
Glia Maturation Factor beta M86492 P17774 Z11558 Q63228 7.6-fold 2 – 6 0.04-fold 21 days
High Mobility Group Protein 1 M23619 P17096 M64986 P27109 4.3-fold 2 – 37 3-fold 4 h – 3 d
P27428 0.3-fold 21 days
Early Growth Response Protein 1 X52541 P18146 M18416 P08154 4.4-fold 2 – 20 3.9-fold 1 h – 12 h
M62829 J04154 0.2-fold 21 days
TAT-Binding Protein 1 M34079 P17980 U77918 P97638 3.8-fold 2 – 20 0.4-fold 21 days
Glutathione S-Transferase 1 J03746 P10620 J03752 P08011 17.5-fold 2 – 20 10.8-fold 24 h – 21 d
Fibroblast Growth Factor Receptor 1 M63887 Q02063 D12498 Q04589 10.1-fold 2 – 20 4-fold 4 h – 24 h
M63888 Q02065
M63889
Interleukin 10 M57627 P22301 L02926 P29456 2.4-fold 2 – 20 26 – 37 6.4-fold 21 days
Q63263 0.2-fold
Heat Shock Protein 27 X54079 P04792 M86389 P42930 0.6-fold 2 – 20 15.2-fold 4 h – 24 h
Heat Shock Protein 70 M11717 P08107 Z27118 Q63718 0.6-fold 2 – 6 9.4-fold 1 h – 24 h
P19790
Thioredoxin Peroxidase 1 L19185 P32119 U06099 P35704 4.9-fold 2 – 20 3.9-fold 21 days
X82321 P31945
Platelet-Derived Growth Factor A X06374 P04085 L06894 P28576 1.6-fold 2 – 6 0.5-fold 21 days
Matrix Metalloproteinase 14 X83535 Q92678 X83537 Q10739 6.9-fold 2 – 6 3.3-fold 24 h – 3 d
Kinase receptor TYRO3 Sky proto-oncogene D17517 Q06418 D37880 P55146 3.1-fold 9 – 20 4.0-fold 24 h – 3 d
0.4-fold 21 days
CSF-1-Receptor X03663 P07333 X61479 Q00495 89.2-fold 9 – 20 2.8-fold 3 days
Insulin-like Growth Factor Binding Protein 2 M35410 P18065 J04486 P12843 79.7-fold 9 – 20 2.1-fold 3 days
Mitogen activated kinase 1/2 M84489 P28482 M64300 P27703 48.6-fold 9 – 20 0.3-fold 21 days
Aquaporin 4 U34846 P55087 U14007 P47863 18-fold 9 – 20 3.2-fold 3 days
erbB2 proto-oncogene Neu proto-oncogene M95667 P04626 X03362 P06494 11.2-fold 9 – 20 2.7-fold 12 hrs
M11730 Q14256
L-type calcium channel β3 U07139 P54284 M88751 P54287 10.3-fold 9 – 20 8.6-fold 21 days
Ras-related protein RAB3A M28210 P20336 X06889 P05713 13.9-fold 9 – 20 0.3-fold 21 days
CAMK-II beta U50358 Q13554 M16112 P08413 1.8-fold 9 – 20 0.3-fold 21 days
Growth Factor Receptor-Bound 2 L29511 Q63057 D49846 Q63057 19.9-fold 9 – 20 2.7-fold 3 days
M96995 Q14450 Q14450
Signal Transducer & Activator of Transcription 3 L29277 P40763 X91810 P52631 0.4-fold 9 – 20 6.6-fold 4 h – 3 d
0.05-fold 21 days
Neuronatin U25033 Q16517 U08290 Q62649 11.1-fold 9 – 20 0.4-fold 21 days
Q62663
Glutathione S-Transferase P X08058 P09211 X02904 P04906 3.1-fold 9 – 20 0.1-fold 1 hr
Glucocorticoid-regulated serine/threonine kinase GSK AJ000512 O00141 L01624 Q06226 0.6-fold 26 – 37 2.4-fold 3 days
0.05-fold 21 days
Glucose Transporter 1 K03195 P11166 M13979 P11167 0.6-fold 26 – 37 11.6-fold 4 h – 21 dBMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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4Ei), but an increase in cytoplasmic and nuclear staining
in neurons occurred following MCAO, in particular at 1 h
and 24 h (Figure 4Eii). Finally, an increase in PAK1
expression was also seen in human foetal neurons follow-
ing oxygen-glucose deprivation (Figure 4Fi and 4Fii).
Discussion and Conclusion
In the human brain, many differentially expressed genes
were observed from 2 to 6 days and from 9 to 20 days after
stroke, with the majority being upregulated. The number
of deregulated genes declined during 26 to 37 days after
stroke, indicating that dynamic changes in gene expres-
sion occur during the first days to few weeks in the human
postischaemic brain. In the rat brain, few differences were
observed at 1 hour, while the number of differentially
expressed genes steadily increased with time after MCAO,
with a peak after 3 days, supporting the concept of active
mechanisms initiated during the acute phase after experi-
mental stroke and lasting for several days. The number of
upregulated genes gradually increased, peaking at 3 days,
while downregulated genes were detected 24 h after
MCAO and increased dramatically until the final meas-
ured time-point at 21 days (Figure 1).
The limitations of post-mortem brain samples in cDNA
microarray analysis concern the small sample size and
potential low quality and the genetic heterogeneity and
diversity in terms of age, sex and previous medical history
within a group of patients [28,29]. We found that analysis
of postischaemic gene expression using a cDNA microar-
ray can allow identification of known and novel transcrip-
tional events, molecular participants and signalling
mechanisms in cerebral ischaemia as previously sug-
gested, but can also detect differences in gene expression
between distinct organisms.
INI1 expression in human brain following stroke Figure 2
INI1 expression in human brain following stroke. RT-
PCR demonstrated an increase in ini1 mRNA levels in inf-
arcted and peri-infarcted areas of pooled samples from 
patients surviving from 2 to 6 days following stroke (A). 
Western blotting showed an increase in protein levels in inf-
arcted and peri-infarcted areas of patients surviving for 3 (Bi) 
and 6 (Bii) days following stroke. Moderate INI1 neuronal 
staining (arrow) in contralateral areas of a patient surviving 
for 3 days after stroke (Ci). Strong INI1 staining in cells 
(arrows) from infarcted areas of a patient surviving for 15 
days after stroke (Cii and iii) (C: Contralateral, P: Peri-infarct, 
I: Infarct).
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ĮDFWLQ±
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Table 4: Protein expression in infarcted (I) and peri-infarcted (P) areas (Fold increase compared to contralateral hemisphere)
PAK1 INI1 MMP11
Patient no. Survival (days) P I P I P I
1 2 2.2 1.0 1.5 1.5 1.5 1.5
2 3 3.3 4.0 0.2 0.4 1.0 1.0
3 3 1.0 1.0 4.2 4.3 0.7 0.7
4 6 1.0 1.0 4.3 5.8 1.6 1.5
5 9 1.5 0.4 3.2 3.3 ND ND
6 15 2.3 1.5 2.8 1.0 1.7 1.6
7 15 3.0 3.2 1.7 2.0 1.0 1.0
8 17 1.0 1.0 1.0 1.0 1.0 1.0
9 20 1.0 1.0 1.0 1.0 1.0 1.0
10 26 1.5 1.5 1.0 1.6 5.1 2.2
11 29 1.0 1.5 2.2 2.8 1.8 3.5
12 37 1.5 1.0 1.7 1.7 1.0 1.5
T o t a l U p r e g u l a t e d 758856
D o w n r e g u l a t e d 011111
N o  c h a n g e 563354
No detection 0 0 0 0 1 1BMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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The present gene expression profile study is the first large-
scale microarray report showing altered expression of sev-
eral genes following human stroke. These included genes
participating in transcription, apoptosis, inflammation
and neuroprotection. Many genes/proteins previously
shown to be deregulated following stroke were reported
in our study too e.g. IL-10 [30,31], PDGF [32], STAT3
[33,34], MAPK1/2 [35]. To test whether our microarray
analysis could predict novel candidate genes involved in
the cerebral response to ischaemia with possible func-
tional importance and significance in stroke-induced neu-
ronal damage, we measured protein expression and
PAK1 expression in human and rat brain following stroke Figure 4
PAK1 expression in human and rat brain following 
stroke. RT-PCR demonstrated an increase in PAK1 mRNA 
in infarcted and peri-infarcted areas of pooled samples from 
patients surviving from 2 to 6 days following stroke (A). 
Western blotting demonstrated an increase in protein levels 
in infarcted and peri-infarcted areas of patients surviving for 3 
(Bi) and 15 (Bii) days following stroke and in rats at 12 h (Ci) 
and 24 h (Cii) following MCAO. Weak neuronal (axonal) 
staining (arrow) observed in contralateral areas of a patient 
surviving for 15 days following stroke (Di). Strong PAK1 
staining in neurons (arrow) and cells with the morphological 
appearance of glia from infarcted areas of a patient surviving 
for 3 days following stroke (Dii). No staining observed in 
contralateral areas of rat brain at 24 h following MCAO (Ei) 
while strong PAK1 staining was seen in neurons (arrow) and 
cells with the morphological appearance of glia from inf-
arcted areas of rat brain 1 h following MCAO (Eii). Stronger 
PAK1 immunofluorescent staining was seen in HFN following 
OGD (Fii) compared to control (Fi) (C: Contralateral, P: 
Peri-infarct, I: Infarct).
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MMP11 expression in human and rat brain following stroke Figure 3
MMP11 expression in human and rat brain following 
stroke. RT-PCR demonstrated an increase in MMP11 
mRNA levels in infarcted and peri-infarcted areas of patients 
surviving from 2 to 6 days following stroke (Ai) and rats at 3 
days after MCAO (Aii). Western blotting demonstrated an 
increase in protein levels in infarcted and peri-infarcted areas 
of patients surviving for 29 (Bi) and 26 (Bii) days following 
stroke. Weak MMP11 staining in cells from contralateral 
areas of a patient surviving for 5 days following stroke (Ci). 
Blood vessels (Cii) and neurons (Ciii) strongly stained for 
MMP11 in peri-infarcted areas of a patient surviving for 15 
days after stroke (arrows). No MMP11 staining observed in 
contralateral hemisphere of rat brain at 1 h after MCAO (Di) 
but neurons from infarcted areas of rat brain were stained 
positive for MMP11 at 3 days following MCAO (Dii) (C: Con-
tralateral, P: Peri-infarct, I: Infarct).
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cellular localisation for three induced genes, INI1, PAK1
and MMP11. They were chosen because they showed at
least 2-fold mRNA induction and there was no prior pub-
lished evidence implicating them in human cerebral
ischaemia.
PAK1 is a downstream Rac effector and a major cyclin-
dependent kinase 5 (Cdk5) substrate and target that co-
localizes with p35/Cdk5 at neuronal peripheries. P35/
Cdk5 causes PAK1 hyperphosphorylation, which results
in PAK1 down-regulation and is likely to have an impact
on the dynamics of the reorganization of the actin
cytoskeleton in neurons during dendrite development
[36]. Based on this evidence, these authors proposed the
existence of a neuron-specific signalling complex involv-
ing Cdk5/p35-PAK1 that inhibits PAK1 activity in neu-
rons. We have recently provided evidence for a potential
role of Cdk5/p35 in the response to ischaemic injury as
we showed association of Cdk5 with nuclear damage, by
demonstrating co-expression of Cdk5 in TUNEL-positive
neurons following human stroke and in propidium
iodide-positive human foetal neurons following OGD
[37]. Here, we have reported for the first time an upregu-
lation in PAK1 protein levels in human and rat brain sam-
ples following MCAO and in HFN following oxygen-
glucose deprivation. Although in the animal model PAK1
protein levels returned to normal 3 days following stroke,
some patients showed elevated levels for PAK1 at later
time-points too. In both human and the animal model,
neurons were the predominant type of cells stained posi-
tive for PAK1.
MMP11 or stromelysin-3 (ST3), first isolated as a breast
cancer-associated protease, is not expressed in the major-
ity of normal adult organs but is expressed during a
number of pathological processes, including wound heal-
ing and atherosclerotic lesions [38,39]. Although other
metalloproteinases have been studied extensively follow-
ing stroke [40,41], there is no report of the expression of
MMP11 following stroke in vivo or in vitro. Here we report
an increase in protein levels of MMP11 following stroke in
both human and rat brain, although the increase seen in
man remained elevated much longer. Although MMP11
shares many similarities with other MMPs, it also differs
in that it exhibits anti-apoptotic properties, a first-known
activity for a MMP [42]. Moreover, although it is expressed
in many processes involving tissue remodelling, cell
migration and cell death, the pathways through which it
participates in pathogenesis remain unclear, largely due to
the lack of information on its substrates in vivo [43].
INI1 is a tumour suppressor gene, thought to exert its
tumour suppressor function by mediating cell cycle arrest
[44]. It was initially identified as a human homolog of
yeast transcriptional activator SNF5 that binds to the HIV-
1 integrase and stimulates its DNA-joining activity [45].
Brains of AIDS patients had been shown to manifest neu-
ronal injury and apoptotic-like cell death raising the ques-
tion about the way HIV-1 resulted in neuronal damage,
since neurons themselves are very rarely infected by the
virus [46]. Adler et al. [47] also reported an association of
the human SNF5/INI1 protein with growth arrest and
DNA damage-inducible protein 34 (GADD34) that medi-
ates growth arrest and apoptosis in response to stress sig-
nals [48,49]. Our study is the first to suggest a potential
role for INI1 in pathways activated after stroke with a pos-
sible role in brain injury. However, in the animal model
study, INI1 levels remained unchanged following stroke.
The reason for this discrepancy warrants further studies.
Many experimental trials of stroke therapies have failed to
translate to human clinical trials and one possible way to
improve the success rate can be through comparative
genomics. As it has been recently commented, it is very
surprising that the exciting developments observed in
basic and clinical stroke research over the past two dec-
ades have occurred in parallel, with too little direct trans-
lation between bench and bedside [50]. Here, we have
provided substantial evidence that, although the available
animal models of MCAO may well be suitable to study the
pathophysiological changes following the occlusion of a
cerebral vessel, they may not entirely reflect the patho-
physiological process through which stroke evolves in
humans. The species difference is one of the main reasons
accounting for the lack of success of bench to bedside
translation in the stroke area. Limitations of our study
include the fact that early acute phase changes in gene
expression may have been missed since genes induced
and returning to normal during the first 48 hours post-
ischaemia in man could not have been detected. Moreo-
ver, since we analyzed pooled RNA samples, small
changes in gene expression occurring in a minority of the
samples may have been missed. However, there was only
a small overlap of our results with prior studies in experi-
mental stroke involving brain tissue, and the successful
identification of novel ischaemia-related genes reported
here suggests that performing a further study using whole
genome microarrays would be valuable.
Methods
Human brain autopsy specimens
Human brain tissue samples were obtained from 12
patients who died from acute ischaemic stroke, with the
approval of the local Ethics Committee and Brain Bank at
the Department of Neuropathology, Collegium Medicum,
Jagiellonian University, Krakow, Poland. All patients were
admitted with large middle cerebral artery strokes con-
firmed by CT-scan or MRI. The patients, 10 male and 2
female, were aged between 51 and 86 years and had sur-
vived between 2–37 days following ischaemic strokeBMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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(Table 2). Routine blood parameters were determined on
admission. Full clinical examinations, including NIH
Stroke Scale, were also carried out on admission. Excluded
from the study were patients with recent history of head
trauma, major cardiac, renal, hepatic or cancerous disease
and obvious signs of infection after admission. Immedi-
ately after death the body was put in a cold chamber and
tissue was collected within 6 h of death. Tissue samples
were taken from infarct and peri-infarcted zones while
controls were obtained from the contralateral hemisphere
at the same time. The peri-infarcted areas were defined in
tissue sections as the tissue immediately surrounding the
infarcted core which contained some necrotic cells and
showed evidence of tissue disorganisation confirmed by
histology. Sections were stained with 2,3,5-triphenyltetra-
zolium chloride which stains active mitochondria pink;
therefore, non stained areas represented stroke affected
cortical regions (data not included). Tissue specimens
were immediately frozen in liquid nitrogen, kept at -70°C
and a portion of each sample was processed for histology
and stained with haematoxylin and eosin to determine
tissue morphology [51].
Rat middle cerebral artery occlusion
Stroke experiments were performed on female Sprague-
Dawley rats (weight: 230–270 g) as they suffer less than
male during ischaemia. Cerebral ischaemia was produced
using a modified method of Baron [52] by distal, perma-
nent occlusion of the MCA by electrocautery as described
elsewhere [53,54]. The mortality in this model is very low.
Sets of six animals (3 for morphological studies and 3
pooled together) for each time-point were sacrificed at 1
h, 4 h, 12 h, 24 h and 3, 7 and 21 days.
In vitro oxygen-glucose deprivation (OGD)
Human brain microvascular endothelial cells (HBMEC)
were obtained from TCS CellWorks (Buckingham, UK)
and cultured according to the supplier's instructions.
Human foetal (cerebral cortical) neurons (HFN) were
extracted and cultured with permission from the Local
Ethics Committee. Brain tissue from foetus specimens of
14–19 weeks gestational age, legally aborted and with the
appropriate written consent, were collected in cold preser-
vation medium and cells were isolated and cultured as
described elsewhere [55]. For OGD experiments, the cul-
ture medium was replaced by glucose-free medium con-
taining 2% foetal bovine serum (TCS CellWorks,
Buckingham, UK) and cells were cultured at 37°C in a
humidified chamber with 94% N2, 1% O2, and 5% CO2
for 6 h (HBMEC) or 95% N2 and 5% CO2 for 14 h (HFN)
followed by 24 h reperfusion in fresh medium containing
4.5 g/l glucose. This resulted in approximately 30% of
cells undergoing apoptosis after OGD and 60% following
reoxygenation, as determined from our pilot studies. Cells
cultured in normoxic conditions without glucose depriva-
tion were used as controls. In some experiments, propid-
ium iodide (10 μg/ml) was added to the cultures 1 h
before the end of the experiment to stain dead and dying
cells.
cDNA microarrays
We established mRNA expression profiles of the damaged
brain tissues between 2 to 6 days, 9 to 20 days, and 26 to
37 days after stroke in human patients and 1, 4, 12, 24
hours and 3, 7 and 21 days after the ischaemic insult in
rats. The corresponding samples from the non-ischemic
control hemisphere were used to measure the normal
mRNA abundance of the modulated genes in each tissue
at each time point. RNA from three stroke patients was
pooled for each patient survival group while RNA from
three MCAO rats was also pooled at each time-point to
improve yields in preparation of poly A+ RNA. Although
pooling was previously thought to affect data quality,
Kendziorski et al. [56] have recently shown that inference
was not adversely affected by pooling. The different
patient groups were selected to match the three physiolog-
ical stages following stroke i.e. the inflammatory (lasting
up to a maximum of 5–6 days), the proliferative (lasting
up to three weeks following stroke) and the remodelling/
maturation (starting during the third or fourth week).
RNA was extracted according to the manufacturer's proto-
cols (BD Biosciences, Oxfordshire, UK) and its quality was
measured spectrophotometically. The protocol recom-
mended by Clontech in their Atlas 1.2 microarray kit was
used without any modification. Briefly, RNA was reverse-
transcribed to cDNA, 32P-labelled and applied to the array
for overnight hybridisation at 68°C. Following washing,
the array was exposed to a phosphorimaging plate for
12–72 hours and data analysis was performed using the
AtlasImage 1.5 software. The results were normalized
using two housekeeping genes, ubiquitin and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH). As in the
majority of microarray studies mentioned before, only
those genes upregulated > 2-fold or downregulated < 0.5-
fold were counted as deregulated and taken into consider-
ation. The microarray data are available in Gene Expres-
sion Omnibus under the accession number GSE9391.
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR)
Gene expression was examined by semi-quantitative RT-
PCR with standard reaction conditions of a 10 min dena-
turation at 94°C, followed by 35 cycles of 1 min at 94°C,
1 min at primer-specific annealing temperatures (Table 5)
and 1 min at 72°C and a final 10 min extension step at
72°C. Samples without cDNA were used as negative con-
trols and the products were visualized by agarose gel elec-
trophoresis (1.5% w/v) and DNA stained with ethidium
bromide (10 mg/ml). All experiments were carried out atBMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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25, 30, 35 and 40 cycles to ensure the semi-quantitative
nature of the results. The results were normalized using
housekeeping gene GAPDH and semi-quantitavely ana-
lyzed using Scion Imaging Software version 4.02 (Scion
Corporation, Maryland, USA). Sense and antisense oligo-
nucleotide primers containing 18–27 nucleotides based
on previously reported mRNA sequences in the GenBank
depository were designed with the aid of the Primer3 Out-
put Program (Version 0.2). InVitrogen plc. (Paisley, UK)
synthesized the primer sets (Table 5).
Protein extraction and Western blotting
Proteins were extracted from tissues and the protein con-
centration of each sample was determined using the Bio-
Rad assay. For Western blotting, 10 μg of protein were
separated by SDS-PAGE (13% w/v) and the proteins were
electro-blotted onto nitrocellulose filters as described pre-
viously [57]. Filters were blocked in 1% w/v bovine serum
albumin (BSA) in Tris-buffered saline Tween (TBS Tween)
and stained overnight at 4°C with antibodies to the fol-
lowing proteins (obtained from Autogen Bioclear, Wilt-
shire, UK, unless stated otherwise) diluted in 1% BSA:
MMP11 (CalBiochem; 1:500), PAK1 (1:500), INI1
(1:500), and α-actin (Sigma, 1:1000) used as a loading
control. Membranes were washed in TBS-Tween before
staining with the appropriate peroxidase-conjugated sec-
ondary antibody, diluted 1:1000 in 5% w/v milk in TBS-
Tween for l h. Blots were developed with the ECL detec-
tion system (Amersham, UK). The relative intensities of
the bands were measured in an LKB densitometer. Results
are semi-quantitative and are given as a numerical (fold)
change compared to the control (contralateral tissue)
which was given an arbitrary value of 1.0. All experiments
were performed twice and a representative example of
patient(s) showing an increase in protein expression is
given.
Immunohistochemistry/Immunofluorescence
Paraffin-embedded tissue samples were processed and
serial 5 μm sections were cut. The Avidin-Biotin Peroxi-
dase (ABC Vectastain kit, Vector Laboratories, Peterbor-
ough, UK) method was used and antibodies to MMP11,
PAK1 and INI1 were used at a dilution of 1:50. Paraffin-
embedded sections were deparaffinized, rehydrated and
boiled for 10 min in an antigen unmasking solution of
concentrated citric acid pH 6.0 as described elsewhere
[57]. Slides were incubated in 0.5% v/v H2O2 in methanol
for 30 min, with normal serum for 20 min and then with
a primary antibody (diluted in normal serum) for 30 min,
followed by 30-min incubation with biotinylated second-
ary antibody (diluted 1:50) and finally with ABC complex
(diluted 1:50) for 30 min at RT. Staining was completed
after incubation with DAB substrate chromogen solution
for 3–10 min. Slides were counterstained with haematox-
ylin, dehydrated, cleared and mounted in DPX. For
immunofluorescence, cultured cells were fixed in 4%
paraformaldehyde for 20 min, permeabilized with 0.2%
Triton ×100 for 10 min, blocked with normal serum and
stained with the primary antibody as above, followed by
1 h incubation with Alexa-fluor conjugated dye at RT.
Negative control slides were performed in parallel, where
primary antibody was replaced with washing buffer and
processed as above (data not included).
Abbreviations
GAPDH: glyceraldehyde 3-phosphate dehydrogenase;
HBMEC: human brain microvascular endothelial cells;
HFN: human foetal neurons; INI1: integrase interactor 1;
MCAO: middle cerebral artery occlusion; MMP11: matrix
metalloproteinase; OGD: oxygen-glucose deprivation;
PAK1: p21-activated kinase 1.
Table 5: Primer sequences
Gene Species Primer Sequence T annealing
mmp11 Human 5'-TAAAGGTATGGAGCGATGTGAC-3' (forward) 58°C
mmp11 5'-TGGGTAGCGAAAGGTGTAGAAG-3' (reverse)
mmp11 Rat 5'-GATGGAGGCCAGCTAGTCAG-3' (forward) 60°C
mmp11 5'-ATGGTACATGACCACGCAGA-3' (reverse)
ini1 Human 5'-ACCCTGTCCAACAGCTCCCA-3' (forward) 64°C
ini1 5'-GGCCCAATCTTCTGAGATGC-3' (reverse)
ini1 Rat 5'-CCTGGGGCTCCTATACAAAA-3' (forward) 60°C
ini1 5'-CCATGACCGAGCAAATGAC-3' (reverse)
pak1 Human 5'-GCTGTTCTGGATGTGTTGGA-3' (forward) 60°C
pak1 5'-TCTGCTCTGGGGTTATCTGTG-3' (reverse)
pak1 Rat 5'-AGCAAAAGAGGCAACCAAGA-3' (forward) 60°C
pak1 5'-GGGTAAGGAATGGGATGGTT-3' (reverse)
gapdh Human 5'-ATGATCTTGAGGCTGTTG-3' (forward) 58°C
gapdh 5'-CTCAGACACCATGGGGAA-3' (reverse)BMC Neuroscience 2007, 8:93 http://www.biomedcentral.com/1471-2202/8/93
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